| Title: | Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease |
| Journal: | Circulation |
| Published: | 8 Nov 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37937463/ |
| DOI: | https://doi.org/10.1161/circulationaha.123.066822 |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 9273
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production and catabolism may provide therapeutic benefit, but little is known about Lp(a) cellular uptake.</p>
METHODS: Here, unbiased ligand-receptor capture mass spectrometry was used to identify MFSD5 (major facilitator superfamily domain containing 5) as a novel receptor/cofactor involved in Lp(a) uptake.</p>
RESULTS: Reducing MFSD5 expression by a computationally identified small molecule or small interfering RNA suppressed Lp(a) uptake and calcification in primary human valvular endothelial and interstitial cells. MFSD5 variants were associated with aortic stenosis (P=0.027 after multiple hypothesis testing) with evidence suggestive of an interaction with plasma Lp(a) levels.</p>
CONCLUSIONS: MFSD5 knockdown suppressing human valvular cell Lp(a) uptake and calcification, along with meta-analysis of MFSD5 variants associating with aortic stenosis, supports further preclinical assessment of MFSD5 in cardiovascular diseases, the leading cause of death worldwide.</p>
20 Authors
- Maximillian A. Rogers
- Francesca Bartoli-Leonard
- Kang H. Zheng
- Aeron M. Small
- Hao Yu Chen
- Cassandra L. Clift
- Takaharu Asano
- Shiori Kuraoka
- Mark C. Blaser
- Katelyn A. Perez
- Pradeep Natarajan
- Calvin Yeang
- Erik S.G. Stroes
- Sotirios Tsimikas
- James C. Engert
- George Thanassoulis
- Christopher J. O'Donnell
- Masanori Aikawa
- Sasha A. Singh
- Elena Aikawa
1 Application
| Application ID | Title |
|---|---|
| 41025 | Pleiotropic effects of cardiometabolic genetic markers and their interaction with diet and fatty acids in cardiovascular diseases. |
Enabling scientific discoveries that improve human health